Meta-analysis of efficacy and safety of new oral anticoagulants compared with uninterrupted Vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation

American Journal of Cardiology

Volumn 117, Issue 6, 2016, Pages 926-934

  Wu, Shuang ^a   Yang, Yan Min ^a   Zhu, Jun ^a   Wan, Huai Bin ^a   Wang, Juan ^a   Zhang, Han ^a   Shao, Xing Hui ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN; PROTHROMBIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; GROIN HEMATOMA; HEART TAMPONADE; HEMATOTHORAX; HEMOPTYSIS; HUMAN; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; ANTAGONISTS AND INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DABIGATRAN; FACTOR XA INHIBITORS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; OBSERVATIONAL STUDIES AS TOPIC; PROTHROMBIN; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIVAROXABAN; STROKE; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84959506562     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.12.027     Document Type: Article

References (30)

1. L.C. Kok, J.M. Mangrum, D.E. Haines, and J. Mounsey Cerebrovascular complication associated with pulmonary vein ablation J Cardiovasc Electrophysiol 13 2002 764 767
2. R. Nairooz, P. Sardar, J. Payne, W.S. Aronow, and H. Paydak Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation Int J Cardiol 187 2015 426 429
3. M. Bassiouny, W. Saliba, J. Rickard, M. Shao, A. Sey, M. Diab, D.O. Martin, A. Hussein, M. Khoury, B. Abi-Saleh, S. Alam, J. Sengupta, P.P. Borek, B. Baranowski, M. Niebauer, T. Callahan, N. Varma, M. Chung, P.J. Tchou, M. Kanj, T. Dresing, B.D. Lindsay, and O. Wazni Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation Circ Arrhythm Electrophysiol 6 2013 460 466
4. D.W. Kaiser, M.M. Streur, R. Nagarakanti, S.P. Whalen, and C.R. Ellis Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter J Interv Card Electrophysiol 37 2013 241 247
5. A. Arshad, C.K. Johnson, S. Mittal, E. Buch, I. Hamam, T. Tran, R.E. Shaw, D. Musat, M. Preminger, T. Sichrovsky, B. Herweg, K. Shivkumar, J. Hummel, and J.S. Steinberg Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study Pacing Clin Electrophysiol 37 2014 665 673
6. H. Ichiki, N. Oketani, S. Ishida, Y. Iriki, H. Okui, R. Maenosono, F. Namino, Y. Ninomiya, M. Miyata, S. Hamasaki, and C. Tei The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran Pacing Clin Electrophysiol 36 2013 1328 1335
7. K. Kaseno, S. Naito, K. Nakamura, T. Sakamoto, T. Sasaki, N. Tsukada, M. Hayano, S. Nishiuchi, E. Fuke, Y. Miki, K. Nakamura, E. Yamashita, K. Kumagai, S. Oshima, and H. Tada Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation Circ J 76 2012 2337 2342
8. D. Lakkireddy, Y.M. Reddy, L. Di Biase, S.R. Vanga, P. Santangeli, V. Swarup, R. Pimentel, M.C. Mansour, A. D'Avila, J.E. Sanchez, J.D. Burkhardt, F. Chalhoub, P. Mohanty, J. Coffey, N. Shaik, G. Monir, V.Y. Reddy, J. Ruskin, and A. Natale Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation J Am Coll Cardiol 59 2012 1168 1174
9. H. Yamaji, T. Murakami, K. Hina, S. Higashiya, H. Kawamura, M. Murakami, S. Kamikawa, S. Hirohata, and S. Kusachi Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation Clin Drug Investig 33 2013 409 418
10. J.-S. Kim, F. She, K. Jongnarangsin, A. Chugh, R. Latchamsetty, H. Ghanbari, T. Crawford, A. Suwanagool, M. Sinno, T. Carrigan, R. Kennedy, W. Saint-Phard, M. Yokokawa, E. Good, F. Bogun, F. Pelosi, F. Morady, and H. Oral Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation Heart Rhythm 10 2013 483 489
11. G. Stepanyan, N. Badhwar, R.J. Lee, G.M. Marcus, B.K. Lee, Z.H. Tseng, V. Vedantham, J. Olgin, M. Scheinman, and E.P. Gerstenfeld Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation J Interv Card Electrophysiol 40 2014 33 38
12. M. Bernard, W. Brabham, P. Netzler, C. Rowley, M. Gold, R. Leman, J. Sturdivant, J.M. Wharton, and F. Cuoco Comparison of atrial fibrillation ablation bleeding and thrombotic complications with dabigatran, rivaroxaban and warfarin J Am Coll Cardiol 61 2013 E276
13. L.I. Garcia, K. Ahuja, M.A. Mascarenhas, A. Aizer, N. Bernstein, S.A. Bernstein, S.J. Fowler, D.S. Holmes, D.S. Park, and L. Chinitz The safety of dabigatran versus warfarin in patients undergoing atrial fibrillation ablation Heart Rhythm 10 2013 S236 S237
14. S. Hirose, K. Miyamoto, I. Nakajima, K. Ishibashi, H. Okamura, T. Noda, T. Aiba, S. Kamakura, and K. Kusano Discontinuation period and periprocedural events of novel oral anticoagulation in patients undergoing catheter ablation of atrial fibrillation Eur Heart J 35 2014 30
15. D.G. Shin, T.H. Kim, J. Park, H. Lee, J.K. Park, J.S. Uhm, J.Y. Kim, B. Joung, M.H. Lee, and H.N. Pak Novel oral anticoagulants reduces preprocedural anticoagulation duration, but increases intra-procedural heparin requirement compared to uninterrupted warfarin in atrial fibrillation catheter ablation Heart Rhythm 12 2015 S260
16. H. Toyama, and K. Kumagai Relationship between oral anticoagulants and dose of heparin during procedure in patients undergoing catheter ablation of atrial fibrillation Heart Rhythm 11 2014 S310 S311
17. L. Di Biase, C. Trivedi, P. Mohanty, S. Mohanty, R. Bai, P. Santangeli, J. Sanchez, R. Horton, G. Joseph Gallinghouse, J. Zagrodzky, S. Hao, R. Hongo, S. Beheiry, D.R. Lakkireddy, M. Reddy, J.F. Viles-Gonzalez, J. David Burkhardt, and A. Natale Feasibility and safety of uninterrupted rivaroxaban in patients undergoing radiofrequency ablation for long standing persistent atrial fibrillation Circulation 130 2014 A16402
18. C. Wunderlich, M. Christoph, Y. Huo, M. Forkmann, T. Gaspar, J. Salmas, M. Pohl, J. Mayer, and C. Piorkowski Ablation of atrial fibrillation with uninterrupted NOAC treatment during ablation of atrial fibrillation is not associated with severe peri- and postprocedural complications Europace 17 2015 iii234 iii236
19. L. Di Biase, D. Lakkireddy, C. Trivedi, T. Deneke, M. Martinek, S. Mohanty, P. Mohanty, S. Prakash, R. Bai, M. Reddy, C. Gianni, R. Horton, S. Bailey, E. Sigmund, M. Derndorfer, A. Schade, P. Mueller, A. Szoelloes, J. Sanchez, A. Al-Ahmad, P. Hranitzky, G.J. Gallinghouse, R.H. Hongo, S. Beheiry, H. Purerfellner, J.D. Burkhardt, and A. Natale Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study Heart Rhythm 12 2015 1162 1168
20. R. Cappato, F.E. Marchlinski, S.H. Hohnloser, G.V. Naccarelli, J. Xiang, D.J. Wilber, C.S. Ma, S. Hess, D.S. Wells, G. Juang, J. Vijgen, B.J. Hugl, R. Balasubramaniam, C. De Chillou, D.W. Davies, L.E. Fields, and A. Natale Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation Eur Heart J 36 2015 1805 1811
21. R. Dillier, S. Ammar, G. Hessling, B. Kaess, H. Pavaci, A. Buiatti, V. Semmler, S. Kathan, M. Hofmann, C. Lennerz, C. Kolb, T. Reents, and I. Deisenhofer Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures Circ Arrhythm Electrophysiol 7 2014 576 582
22. B.M. Kaess, S. Ammar, T. Reents, R. Dillier, C. Lennerz, V. Semmler, C. Grebmer, F. Bourier, A. Buiatti, C. Kolb, I. Deisenhofer, and G. Hessling Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon Am J Cardiol 115 2015 47 51
23. D. Lakkireddy, Y.M. Reddy, L. Di Biase, A. Vallakati, M.C. Mansour, P. Santangeli, S. Gangireddy, V. Swarup, F. Chalhoub, D. Atkins, S. Bommana, A. Verma, J.E. Sanchez, J.D. Burkhardt, C.D. Barrett, S. Baheiry, J. Ruskin, V. Reddy, and A. Natale Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 63 2014 982 988
24. W. Maddox, G.N. Kay, T. Yamada, J. Osorio, H. Doppalapudi, V.J. Plumb, A. Gunter, and H.T. McElderry Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation J Cardiovasc Electrophysiol 24 2013 861 865
25. T. Nagao, Y. Inden, S. Yanagisawa, H. Kato, S. Ishikawa, S. Okumura, Y. Mizutani, T. Ito, T. Yamamoto, N. Yoshida, M. Hirai, and T. Murohara Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation Heart Rhythm 12 2015 1972 1978
26. T. Nagao, Y. Inden, M. Shimano, M. Fujita, S. Yanagisawa, H. Kato, S. Ishikawa, A. Miyoshi, S. Okumura, S. Ohguchi, T. Yamamoto, N. Yoshida, M. Hirai, and T. Murohara Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation Pacing Clin Electrophysiol 38 2015 155 163
27. T. Nagao, Y. Inden, M. Shimano, M. Fujita, S. Yanagisawa, H. Kato, S. Ishikawa, A. Miyoshi, S. Okumura, S. Ohguchi, T. Yamamoto, N. Yoshida, M. Hirai, and T. Murohara Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation Intern Med 54 2015 1167 1173
28. L.R. Jackson Ii, and R.C. Becker Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal J Thromb Thrombolysis 37 2014 380 391
29. P. Sardar, R. Nairooz, S. Chatterjee, J. Wetterslev, J. Ghosh, and W.S. Aronow Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation Am J Cardiol 113 2014 1173 1177
30. G. Santarpia, S. De Rosa, A. Polimeni, S. Giampa, M. Micieli, A. Curcio, and C. Indolfi Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis PLoS One 10 2015 e0126512